Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 19/20 | 0.57 |
| ▸ | BCL2 | P10415 | 10/20 | 0.57 |
| ▸ | MDM4 | O15151 | 1/20 | 0.55 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | BID | P55957 | 1/20 | 0.55 |
| ▸ | BAX | Q07812 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | ASPH | Q12797 | 1/20 | 0.55 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.55 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.55 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.55 |
| ▸ | BAD | Q92934 | 1/20 | 0.55 |
| ▸ | BBC3 | Q9BXH1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30600379 | 1.00 | BCL2L1 (0.57) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL19424225 | 0.94 | BCL2L1 (0.65) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL19424413 | 0.93 | BCL2L1 (0.63) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL19424421 | 0.93 | BCL2L1 (0.57) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL26682009 | 0.91 | BCL2L1 (0.56) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL19424417 | 0.91 | BCL2L1 (0.57) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL30600371 | 0.90 | BCL2L1 (0.70) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL26682294 | 0.90 | BCL2L1 (0.70) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL26680363 | 0.88 | BCL2L1 (0.60) | BCL2L1BCL2MCL1BCL2L2 | |
| SCHEMBL26844962 | 0.87 | BCL2L1 (0.47) | BCL2L1BCL2MDM4BCL2L11TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
| CN-116829524-A | Method for alkylating acidic functional groups | 中外制药株式会社 | 2023-09-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | BCL2L1 650/4885BCL2 131/4885MDM4 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.